Want to see DE:RDC full AI Analyst Report?
Top Page
Redcare Pharmacy
(XETRA:RDC)
Select Model
Select Model
Rating:56Neutral
Price Target:
€77.00
▲(21.26% Upside)
Action:Reiterated
Date:10/08/26
The score is held back primarily by weak financial quality—continued net losses and a recent TTM reversal into negative operating cash flow and sharply negative free cash flow—despite strong revenue growth and an improved, low-debt balance sheet. Technicals are a key positive with a clear uptrend and supportive momentum, while valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
Strong Revenue Growth
Rapid revenue expansion demonstrates increasing customer adoption and a growing market presence for Redcare Pharmacy. If maintained, this scale can improve purchasing leverage, support operating efficiencies, and provide a broader base for converting growth into sustainable profitability.
Negative Factors
Persistent Net Losses
Despite strong sales growth and improving EBITDA, Redcare Pharmacy has not yet produced consistent bottom-line profitability. Persistent net losses can erode equity over time, limit self-funded expansion, and show that the current operating model still needs further efficiency or margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid revenue expansion demonstrates increasing customer adoption and a growing market presence for Redcare Pharmacy. If maintained, this scale can improve purchasing leverage, support operating efficiencies, and provide a broader base for converting growth into sustainable profitability.
Read all positive factors
Redcare Pharmacy (RDC) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.56B
Dividend YieldN/A
Average Volume (3M)104.62K
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue Growth20.23%
EPS Growth-20.32%
CountryDE
Employees2,163
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-2.09
Shares Outstanding20,578,390
10 Day Avg. Volume81,452
30 Day Avg. Volume104,624
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.85
Price to Sales (P/S)0.45
P/FCF Ratio-23.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€97.00Price Target Upside52.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.28
Revenue Forecast (FY)€3.45B
Redcare Pharmacy Business Overview & Revenue Model
Company Description
Redcare Pharmacy N.V. manages and runs a network of digital pharmacies across Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. The company offers a comprehensive selection of healthcare products, including prescription m...
How the Company Makes Money
Redcare Pharmacy primarily makes money by selling pharmacy and health-related products to consumers through its online channels. Its core revenue streams are: (1) Prescription (Rx) medications: revenue is generated when customers order reimbursabl...
Redcare Pharmacy Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
64
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.22B | 2.94B | 2.37B | 1.80B | 1.20B | 1.06B |
| Gross Profit | 652.03M | 593.70M | 545.78M | 440.38M | 331.79M | 266.53M |
| EBITDA | 67.99M | 45.60M | 28.03M | 50.94M | -30.64M | -37.37M |
| Net Income | -42.04M | -37.70M | -45.46M | -12.04M | -77.65M | -74.19M |
Balance Sheet | ||||||
| Total Assets | 1.15B | 1.25B | 1.00B | 1.02B | 729.47M | 783.08M |
| Cash, Cash Equivalents and Short-Term Investments | 118.90M | 203.50M | 177.56M | 204.16M | 184.00M | 283.46M |
| Total Debt | 354.70M | 415.60M | 247.38M | 244.84M | 255.19M | 236.43M |
| Total Liabilities | 679.50M | 767.30M | 493.31M | 469.56M | 374.84M | 367.66M |
| Stockholders Equity | 457.30M | 459.20M | 483.98M | 522.19M | 354.63M | 415.41M |
Cash Flow | ||||||
| Free Cash Flow | -97.63M | -56.30M | 13.38M | 23.23M | -82.64M | -31.52M |
| Operating Cash Flow | -11.46M | 23.00M | 22.13M | 61.46M | -29.11M | 11.63M |
| Investing Cash Flow | 75.33M | -151.40M | 8.38M | -59.96M | -138.01M | -84.30M |
| Financing Cash Flow | -82.36M | 124.10M | -17.94M | 15.05M | -13.52M | 229.59M |
Redcare Pharmacy Technical Analysis
Positive
63.50
Price Trends
64.28
Positive
63.82
Positive
57.26
Positive
Market Momentum
3.75
Negative
64.57
Neutral
87.97
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:RDC, the sentiment is Positive. The current price of 63.5 is below the 20-day moving average (MA) of 70.92, below the 50-day MA of 64.28, and above the 200-day MA of 57.26, indicating a bullish trend. The MACD of 3.75 indicates Negative momentum. The RSI at 64.57 is Neutral, neither overbought nor oversold. The STOCH value of 87.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:RDC.
Redcare Pharmacy Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | €1.56B | -37.49 | -9.00% | ― | 20.23% | -20.32% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €1.53B | 43.42 | 4.19% | 1.71% | ― | ― | |
51 Neutral | €18.96M | -1.33 | -127.78% | ― | ― | ― | |
51 Neutral | €11.82M | -15.62 | -4.38% | 4.59% | 1.58% | -148.73% | |
42 Neutral | €103.86M | -3.38 | 200.64% | ― | 206.78% | -13.94% |
* General Sector Average
DE:RDC
Redcare Pharmacy
78.45
-1.00
-1.26%
DE:B8FK
Biofrontera
3.10
0.43
16.10%
DE:COP
CompuGroup Medical
28.75
5.00
21.04%
DE:GME
Geratherm Medical
2.20
-1.08
-33.01%
DE:HPHA
Heidelberg Pharma AG
2.03
-1.03
-33.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.